Browse by category

ESSENCE trial: Semaglutide 2.4mg demonstrates statistically significant and superior improvements with in people with MASH

Results from part 1 of the ongoing Phase 3 ESSENCE trial - evaluating the effect of once-weekly subcutaneous semaglutide 2.4mg on liver...

ESSENCE trial: Semaglutide 2.4mg demonstrates statistically significant and superior improvements with in people with MASH

9 minutes ago

RESET: Epitomee's drug-free oral hydrogel capsule reduces TBW by at least 5% at 24 weeks

41 minutes ago

GT Metabolic Solutions carries out the first magnetic compression anastomosis cases in the US with the linear magnet technology - the MagDI System

1 hour ago

Weekly Digest